$VNDA
AI分析生成日 May 12, 2026
AI Score
Hold$VNDA
Vanda Pharmaceuticals Inc.
$VNDANASDAQHealthcareSmall-Cap
Vanda Pharmaceuticals develops and commercializes therapies for central nervous system disorders. Key products include Hetlioz for non-24-hour sleep-wake disorder and Fanapt for schizophrenia.
Market Cap
$350.0M
Revenue (TTM)
$250.0M
-5.0%
Net Income (TTM)
$25.0M
-15.0%
EPS (TTM)
$0.45
P/E Ratio
14.0
Dividend Yield
0.0%
52-Week Range
$4.50-$8.00
Beta
0.65
Dimension Scores
Fundamental
58Technical
48Sentiment
52Risk / Reward
60Momentum
45Financial Health
Profitability
63moderate
Growth
48weak
Liquidity
68strong
Solvency
60moderate
Efficiency
56moderate
Valuation, technical analysis, investment thesis, risk assessment and more for $VNDA
Free · No credit card required
免責事項: AI生成の分析は教育目的のみです。投資アドバイスではありません。必ず資格のあるファイナンシャルアドバイザーにご相談ください。